Cover Image
市場調查報告書

癌症生物標記的全球市場 ∼2022年:各種類 (蛋白質生物標記/遺傳基因生物標記)、腫瘤、分析技術、用途 、地區

Cancer Biomarkers Market by Type (Protein Biomarker, Genetic Biomarker), Cancer Type (Breast, Melanoma, Leukemia, Lung), Profiling Technology (Omics, Imaging, Immunoassay, Bioinformatics), Application - Global Forecast to 2022

出版商 MarketsandMarkets 商品編碼 118897
出版日期 內容資訊 英文 269 Pages
訂單完成後即時交付
價格
Back to Top
癌症生物標記的全球市場 ∼2022年:各種類 (蛋白質生物標記/遺傳基因生物標記)、腫瘤、分析技術、用途 、地區 Cancer Biomarkers Market by Type (Protein Biomarker, Genetic Biomarker), Cancer Type (Breast, Melanoma, Leukemia, Lung), Profiling Technology (Omics, Imaging, Immunoassay, Bioinformatics), Application - Global Forecast to 2022
出版日期: 2017年10月05日 內容資訊: 英文 269 Pages
簡介

全球癌症生物標記市場,預計從2017年到2022年以12.2%的年複合成長率發展,預計從2017年的115億3000萬美元,成長到2022年204億8000萬美元的規模。

本報告提供全球癌症 (腫瘤) 生物標記的市場相關分析,技術性概要和市場基本結構、最新趨勢,主要市場促進、阻礙因素,市場規模趨勢預測 (今後6年份),各腫瘤、各類型、各技術、各用途、各地區的詳細趨勢,市場競爭的狀態,今後的技術開發、市場發展的方向性,主要企業簡介等調查、考察。

第1章 簡介

第2章 分析方法

第3章 摘要整理

第4章 重要考察

第5章 市場概要

  • 簡介
  • 市場動態
    • 促進要素
      • 技術進步
      • 癌症的發病數量的增加
      • 在藥物研發、開發階段的癌症生物標記的利用增加
      • 癌症生物標記相關研究的擴大
    • 阻礙要素
      • 不合適的法規、醫療費償付制度
      • 資本投資額的大小和收益、成本比率低
      • 樣品收集、貯存相關技術課題
    • 市場機會
      • 個人化醫療
      • 搭配診斷
      • 新興國家市場
    • 課題
      • 生物標記相關檢驗的臨床性有效性、效用的檢驗

第6章 癌症生物標記市場:各類型

  • 簡介
  • 蛋白質生物標記
  • 遺傳生物標記
  • 其他癌症生物標記

第7章 全球癌症生物標記市場:癌症的各類型

  • 簡介
  • 乳癌
  • 肺癌
  • 大腸癌
  • 前列腺癌
  • 非何杰金氏淋巴瘤
  • 黑色素瘤
  • 白血病
  • 甲狀腺癌
  • 膀胱癌
  • 腎臟癌
  • 其他癌症

第8章 癌症生物標記市場:各分析技術

  • 簡介
    • 體學技術
    • 蛋白質體學
    • 基因學
      • 下一代型定序 (NGS)
      • 聚合物連鎖反應 (PCR)
    • 其他
  • 影像技術
    • 超音波
    • CT (電腦斷層攝影法)
    • MRI (核磁共振成像診斷)
    • 正子放出型電腦斷層攝影法 (PET)
    • 乳房X光攝影
  • 免疫分析法
  • 細胞遺傳學
    • 原位 雜合反應 (ISH)
    • 其他
  • 生物資訊學 (生物資訊學)

第9章 癌症生物標記市場:各用途

  • 簡介
  • 診斷
  • 研究開發
  • 預後前兆
  • 風險評估
  • 其他的用途

第10章 癌症生物標記市場:各地區

  • 簡介
  • 北美
    • 美國
    • 加拿大
  • 歐洲
    • 德國
    • 英國
    • 法國
    • 義大利
    • 西班牙
    • 其他的歐洲各國
  • 亞太地區
    • 日本
    • 其他的亞太地區各國
  • 其他的國家 (ROW)

第11章 競爭環境

  • 市場佔有率排行榜分析

第12章 企業簡介

  • THERMO FISHER SCIENTIFIC
  • BIO-RAD LABORATORIES
  • ROCHE DIAGNOSTICS
  • QIAGEN N.V.
  • ILLUMINA
  • GE HEALTHCARE
  • AGILENT TECHNOLOGIES
  • BIOMERIEUX SA
  • MERCK & CO.
  • ABBOTT LABORATORIES
  • BECTON, DICKINSON AND COMPANY
  • DANAHER CORPORATION
  • MYRIAD GENETICS
  • SYSMEX CORPORATION
  • HOLOGIC
  • QUEST DIAGNOSTICS

第13章 附錄

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: MD 5627

"Global cancer biomarkers market projected to grow at CAGR of 12.2%"

The global cancer biomarkers market is projected to reach USD 20.48 billion by 2022 from USD 11.53 billion in 2017, at a CAGR of 12.2% from 2017 to 2022.

Over the years, the cancer biomarkers market has evolved significantly owing to the rising prevalence of cancer, advancements in omics technologies, increasing healthcare expenditure, growth in R&D funding from government and private bodies, and rising demand for personalized medicine in cancer therapies. However, an unfavorable regulatory and reimbursement scenario and the high capital investments required for biomarker development and validation are some factors expected to restrain the market.

The lung cancer segment is expected to register the highest CAGR'

The cancer biomarkers market on the basis of cancer type is classified into breast, lung, colorectal, prostate, melanoma, leukemia, thyroid, bladder, non-hodgkin's lymphoma, kidney, and other cancers. The lung cancer segment is expected to register the highest CAGR during the forecast period. The increasing company focus on research on lung cancer biomarkers is the key driver for this market. Increased understanding of the morphology of lung carcinogenesis, development of the high-throughput techniques for biomarker discovery, and increased focus on early detection of cancer are propelling the growth of this market.

"North America is expected to dominate the cancer biomarkers market and APAC growing at the highest CAGR"

North America (comprising the US and Canada) is expected to account for the largest share of the global cancer biomarkers market in 2017. The large share of this geographic segment is mainly attributed to the increasing government support for discovery and development of biomarkers, increasing demand for personalized medicine, adoption of advanced omics technologies for biomarker discovery, and rising use of biomarkers in drug discovery and development by pharmaceutical companies in that region. While the APAC region is expected to register the highest CAGR during the forecast period. The APAC cancer biomarkers market, particularly in China, Japan, and India is expected to witness high growth during the forecast period.

Break of primary participants was as mentioned below:

  • By Company Type - Tier 1-40%, Tier 2-30%, and Tier 3-30%
  • By Designation - Director level-18%, C-Level-27%, and Others-55%
  • By Region - North America-50%, Europe-20%, Asia-Pacific-20%, and RoW-10%

Major players in this market that are profiled in the report includes Abbott (US), Affymetrix (US), Roche (Switzerland), Illumina (US), QIAGEN (Netherlands), Agilent (US), Thermo Fisher (US), Merck (US), Becton Dickinson (US), Hologic (US), Danaher (US), and Shimadzu (Japan).

Research Coverage:

From an insight perspective, this research report focuses on qualitative data, market size, and growth of various segments and subsegments, competitive landscape, and company profiles. The qualitative data covers various levels of industry analysis such as market dynamics (drivers, restraints, opportunities, and challenges). The report also offers market sizes and data on the growth of various segments of the industry. It focuses on emerging and high-growth segments, and high-growth regions. The competitive landscape covers growth strategies adopted by industry players in the last three years. The company profiles comprise basic views on key players in the cancer biomarkers market and the product portfolios, developments, and strategies adopted by market players to maintain and increase their market shares in the near future. The above-mentioned market research data, current market size, and forecast of future trends will help key players and new entrants to make the necessary decisions regarding product offerings, geographical focus, change in approach, R&D investments for innovations in products and technologies, and levels of output to remain successful.

Reasons to Buy the Report:

The report will enrich established firms as well as new entrants/smaller firms to gauge the pulse of the market, which in turn would help garner a greater share. Firms purchasing the report could use one or any combination of the below-mentioned five strategies.

The report provides insights on the following pointers:

  • Market Penetration: Comprehensive information on products offered by the top players in the cancer biomarkers market
  • Product/Service Enhancement/Innovation: Detailed insights on the upcoming technologies, research & development activities, and new product launches in the cancer biomarkers market
  • Market Development: Comprehensive information about lucrative emerging markets-the report analyzes the markets for profiling technologies across various regions
  • Market Diversification: Exhaustive information about new products, untapped geographies, and recent developments in the cancer biomarkers market
  • Competitive Assessment: In-depth assessment of market ranking, strategies, products, and manufacturing capabilities of the leading players in the cancer biomarkers market

TABLE OF CONTENTS

1. INTRODUCTION

  • 1.1. OBJECTIVES OF THE STUDY
  • 1.2. MARKET DEFINITION
    • 1.2.1. MARKETS COVERED
    • 1.2.2. YEARS CONSIDERED FOR THE STUDY
  • 1.3. CURRENCY
  • 1.4. LIMITATIONS
  • 1.5. STAKEHOLDERS

2. RESEARCH METHODOLOGY

  • 2.1. MARKET SIZE ESTIMATION
  • 2.2. MARKET BREAKDOWN AND DATA TRIANGULATION
    • 2.2.1. SECONDARY SOURCES
      • 2.2.1.1. Key Industry Insights
  • 2.3. ASSUMPTIONS FOR THE STUDY

3. EXECUTIVE SUMMARY

4. PREMIUM INSIGHTS

  • 4.1. CANCER BIOMARKERS: MARKET SNAPSHOT
  • 4.2. ASIA PACIFIC CANCER BIOMARKERS MARKET, BY PROFILING TECHNOLOGY AND APPLICATION
  • 4.3. CANCER BIOMARKERS MARKET SHARE, BY CANCER TYPE, 2017 VS. 2022
  • 4.4. CANCER BIOMARKERS MARKET SHARE, BY BIOMARKER TYPE, 2015 TO 2022
  • 4.5. CANCER BIOMARKERS MARKET, BY REGION

5. MARKET OVERVIEW

  • 5.1. INTRODUCTION
    • 5.1.1. DRIVERS
      • 5.1.1.1. Technological advancements
      • 5.1.1.2. Rising incidence of cancer
      • 5.1.1.3. Increasing use of cancer biomarkers in drug discovery and development
      • 5.1.1.4. Increasing research on cancer biomarkers
    • 5.1.2. RESTRAINTS
      • 5.1.2.1. Unfavorable regulatory and reimbursement scenario
      • 5.1.2.2. High capital investment and low benefit-cost ratio
      • 5.1.2.3. Technical issues related to sample collection and storage
    • 5.1.3. OPPORTUNITIES
      • 5.1.3.1. Personalized medicine
      • 5.1.3.2. Companion diagnostics
      • 5.1.3.3. Emerging economies
    • 5.1.4. CHALLENGES
      • 5.1.4.1. Proving the clinical validity and utility of biomarker-based tests

6. CANCER BIOMARKERS MARKET, BY BIOMARKER TYPE

  • 6.1. INTRODUCTION
  • 6.2. PROTEIN BIOMARKERS
  • 6.3. GENETIC BIOMARKERS
    • 6.3.1. LUNG CANCER
    • 6.3.2. COLORECTAL CANCER
    • 6.3.3. BREAST CANCER
    • 6.3.4. PROSTATE CANCER
    • 6.3.5. LEUKEMIA
  • 6.4. OTHER CANCER BIOMARKERS

7. CANCER BIOMARKER MARKET, BY CANCER TYPE

  • 7.1. INTRODUCTION
  • 7.2. BREAST CANCER
  • 7.3. LUNG CANCER
  • 7.4. COLORECTAL CANCER
  • 7.5. PROSTATE CANCER
  • 7.6. NON-HODGKIN'S LYMPHOMA
  • 7.7. MELANOMA
  • 7.8. LEUKEMIA
  • 7.9. THYROID CANCER
  • 7.10. BLADDER CANCER
  • 7.11. KIDNEY CANCER
  • 7.12. OTHER CANCER TYPES

8. CANCER BIOMARKERS MARKET, BY PROFILING TECHNOLOGY

  • 8.1. INTRODUCTION
    • 8.1.1. OMICS TECHNOLOGIES
    • 8.1.2. PROTEOMICS
    • 8.1.3. GENOMICS
      • 8.1.3.1. Next-generation sequencing (NGS)
      • 8.1.3.2. Polymerase chain reaction (PCR)
    • 8.1.4. OTHER OMICS TECHNOLOGIES
  • 8.2. IMAGING TECHNOLOGIES
    • 8.2.1. ULTRASOUND
    • 8.2.2. COMPUTED TOMOGRAPHY (CT)
    • 8.2.3. MAGNETIC RESONANCE IMAGING (MRI)
    • 8.2.4. POSITRON EMISSION TOMOGRAPHY (PET)
    • 8.2.5. MAMMOGRAPHY
  • 8.3. IMMUNOASSAYS
  • 8.4. CYTOGENETICS
    • 8.4.1. IN SITU HYBRIDIZATION (ISH)
    • 8.4.2. OTHER CYTOGENETICS-BASED TESTS
  • 8.5. BIOINFORMATICS

9. CANCER BIOMARKERS MARKET, BY APPLICATION

  • 9.1. INTRODUCTION
  • 9.2. DIAGNOSTICS
  • 9.3. RESEARCH AND DEVELOPMENT
  • 9.4. PROGNOSTICS
  • 9.5. RISK ASSESSMENT
  • 9.6. OTHER APPLICATIONS

10. CANCER BIOMARKERS MARKET, BY REGION

  • 10.1. INTRODUCTION
  • 10.2. NORTH AMERICA
    • 10.2.1. US
    • 10.2.2. CANADA
  • 10.3. EUROPE
    • 10.3.1. GERMANY
    • 10.3.2. UK
    • 10.3.3. FRANCE
    • 10.3.4. ITALY
    • 10.3.5. SPAIN
    • 10.3.6. REST OF EUROPE (ROE)
  • 10.4. ASIA PACIFIC
    • 10.4.1. JAPAN
    • 10.4.2. REST OF APAC
  • 10.5. REST OF THE WORLD (ROW)

11. COMPETITIVE LANDSCAPE

  • 11.1. MARKET RANKING ANALYSIS, 2016

12. COMPANY PROFILES (BUSINESS OVERVIEW, PRODUCTS OFFERED, STRENGTH OF PRODUCT PORTFOLIO, BUSINESS STRATEGY EXCELLENCE, RECENT DEVELOPMENTS.)*

  • 12.1. THERMO FISHER SCIENTIFIC
  • 12.2. BIO-RAD LABORATORIES
  • 12.3. ROCHE DIAGNOSTICS
  • 12.4. QIAGEN N.V.
  • 12.5. ILLUMINA
  • 12.6. GE HEALTHCARE
  • 12.7. AGILENT TECHNOLOGIES
  • 12.8. BIOMERIEUX SA
  • 12.9. MERCK & CO.
  • 12.10. ABBOTT LABORATORIES
  • 12.11. BECTON, DICKINSON AND COMPANY
  • 12.12. DANAHER CORPORATION
  • 12.13. MYRIAD GENETICS
  • 12.14. SYSMEX CORPORATION
  • 12.15. HOLOGIC
  • 12.16. QUEST DIAGNOSTICS

*Details on Business Overview, Strength of Product Portfolio, Business Strategy Excellence, Recent Developments, Key relationships might not be captured in case of unlisted companies.

13. APPENDIX

  • 13.1. INSIGHTS OF INDUSTRY EXPERTS
  • 13.2. DISCUSSION GUIDE
  • 13.3. KNOWLEDGE STORE: MARKETSANDMARKETS' SUBSCRIPTION PORTAL
  • 13.4. INTRODUCING RT: REAL-TIME MARKET INTELLIGENCE
  • 13.5. AVAILABLE CUSTOMIZATIONS
  • 13.6. RELATED REPORTS
  • 13.7. AUTHOR DETAILS

LIST OF TABLES

  • TABLE 1: CANCER BIOMARKERS MARKET, BY BIOMARKER TYPE, 2015-2022 (USD MILLION)
  • TABLE 2: GLOBAL PROTEIN CANCER BIOMARKERS MARKET, BY REGION, 2015-2022 (USD MILLION)
  • TABLE 3: NORTH AMERICA: PROTEIN CANCER BIOMARKERS MARKET, BY COUNTRY, 2015-2022 (USD MILLION)
  • TABLE 4: EUROPE: PROTEIN CANCER BIOMARKERS MARKET, BY COUNTRY/REGION, 2015-2022 (USD MILLION)
  • TABLE 5: ASIA PACIFIC: PROTEIN CANCER BIOMARKERS MARKET, BY COUNTRY/REGION, 2015-2022 (USD MILLION)
  • TABLE 6: GLOBAL GENETIC CANCER BIOMARKERS MARKET, BY REGION, 2015-2022 (USD MILLION)
  • TABLE 7: NORTH AMERICA: GENETIC CANCER BIOMARKERS MARKET, BY COUNTRY, 2015-2022 (USD MILLION)
  • TABLE 8: EUROPE: GENETIC CANCER BIOMARKERS MARKET, BY COUNTRY/REGION, 2015-2022 (USD MILLION)
  • TABLE 9: ASIA PACIFIC: GENETIC CANCER BIOMARKERS MARKET, BY COUNTRY/REGION, 2015-2022 (USD MILLION)
  • TABLE 10: GLOBAL OTHER CANCER BIOMARKERS MARKET, BY REGION, 2015-2022 (USD MILLION)
  • TABLE 11: NORTH AMERICA: OTHER CANCER BIOMARKERS MARKET, BY COUNTRY, 2015-2022 (USD MILLION)
  • TABLE 12: EUROPE: OTHER CANCER BIOMARKERS MARKET, BY COUNTRY/REGION, 2015-2022 (USD MILLION)
  • TABLE 13: ASIA PACIFIC: OTHER CANCER BIOMARKERS MARKET, BY COUNTRY/REGION, 2015-2022 (USD MILLION)
  • TABLE 14: GLOBAL CANCER BIOMARKERS MARKET, BY CANCER TYPE, 2015-2022 (USD MILLION)
  • TABLE 15: GLOBAL BREAST CANCER BIOMARKERS MARKET, BY REGION, 2015-2022 (USD MILLION)
  • TABLE 16: NORTH AMERICA: BREAST CANCER BIOMARKERS MARKET, BY COUNTRY, 2015-2022 (USD MILLION)
  • TABLE 17: EUROPE: BREAST CANCER BIOMARKERS MARKET, BY COUNTRY, 2015-2022 (USD MILLION)
  • TABLE 18: ASIA PACIFIC: BREAST CANCER BIOMARKERS MARKET, BY COUNTRY, 2015-2022 (USD MILLION)
  • TABLE 19: GLOBAL LUNG CANCER BIOMARKERS MARKET, BY REGION, 2015-2022 (USD MILLION)
  • TABLE 20: NORTH AMERICA: LUNG CANCER BIOMARKERS MARKET, BY COUNTRY, 2015-2022 (USD MILLION)
  • TABLE 21: EUROPE: LUNG CANCER BIOMARKERS MARKET, BY COUNTRY, 2015-2022 (USD MILLION)
  • TABLE 22: ASIA PACIFIC: LUNG CANCER BIOMARKERS MARKET, BY COUNTRY, 2015-2022 (USD MILLION)
  • TABLE 23: GLOBAL COLORECTAL CANCER BIOMARKERS MARKET, BY REGION, 2015-2022 (USD MILLION)
  • TABLE 24: NORTH AMERICA: COLORECTAL CANCER BIOMARKERS MARKET, BY COUNTRY, 2015-2022 (USD MILLION)
  • TABLE 25: EUROPE: COLORECTAL CANCER BIOMARKERS MARKET, BY COUNTRY, 2015-2022 (USD MILLION)
  • TABLE 26: ASIA PACIFIC: COLORECTAL CANCER BIOMARKERS MARKET, BY COUNTRY, 2015-2022 (USD MILLION)
  • TABLE 27: GLOBAL PROSTATE CANCER BIOMARKERS MARKET, BY REGION, 2015-2022 (USD MILLION)
  • TABLE 28: NORTH AMERICA: PROSTATE CANCER BIOMARKERS MARKET, BY COUNTRY, 2015-2022 (USD MILLION)
  • TABLE 29: EUROPE: PROSTATE CANCER BIOMARKERS MARKET, BY COUNTRY, 2015-2022 (USD MILLION)
  • TABLE 30: ASIA PACIFIC: PROSTATE CANCER BIOMARKERS MARKET, BY COUNTRY, 2015-2022 (USD MILLION)
  • TABLE 31: GLOBAL NON-HODGKIN'S LYMPHOMA BIOMARKERS MARKET, BY REGION, 2015-2022 (USD MILLION)
  • TABLE 32: NORTH AMERICA: NON-HODGKIN'S LYMPHOMA BIOMARKERS MARKET, BY COUNTRY, 2015-2022 (USD MILLION)
  • TABLE 33: EUROPE: NON-HODGKIN'S LYMPHOMA BIOMARKERS MARKET, BY COUNTRY, 2015-2022 (USD MILLION)
  • TABLE 34: ASIA PACIFIC: NON-HODGKIN'S LYMPHOMA BIOMARKERS MARKET, BY COUNTRY, 2015-2022 (USD MILLION)
  • TABLE 35: GLOBAL MELANOMA BIOMARKERS MARKET, BY REGION, 2015-2022 (USD MILLION)
  • TABLE 36: NORTH AMERICA: MELANOMA BIOMARKERS MARKET, BY COUNTRY, 2015-2022 (USD MILLION)
  • TABLE 37: EUROPE: MELANOMA BIOMARKERS MARKET, BY COUNTRY, 2015-2022 (USD MILLION)
  • TABLE 38: ASIA PACIFIC: MELANOMA BIOMARKERS MARKET, BY COUNTRY, 2015-2022 (USD MILLION)
  • TABLE 39: GLOBAL LEUKEMIA BIOMARKERS MARKET, BY REGION, 2015-2022 (USD MILLION)
  • TABLE 40: NORTH AMERICA: LEUKEMIA BIOMARKERS MARKET, BY COUNTRY, 2015-2022 (USD MILLION)
  • TABLE 41: EUROPE: LEUKEMIA BIOMARKERS MARKET, BY COUNTRY, 2015-2022 (USD MILLION)
  • TABLE 42: ASIA PACIFIC: LEUKEMIA BIOMARKERS MARKET, BY COUNTRY, 2015-2022 (USD MILLION)
  • TABLE 43: GLOBAL THYROID CANCER BIOMARKERS MARKET, BY REGION, 2015-2022 (USD MILLION)
  • TABLE 44: NORTH AMERICA: THYROID CANCER BIOMARKERS MARKET, BY COUNTRY, 2015-2022 (USD MILLION)
  • TABLE 45: EUROPE: THYROID CANCER BIOMARKERS MARKET, BY COUNTRY, 2015-2022 (USD MILLION)
  • TABLE 46: ASIA PACIFIC: THYROID CANCER BIOMARKERS MARKET, BY COUNTRY, 2015-2022 (USD MILLION)
  • TABLE 47: GLOBAL BLADDER CANCER BIOMARKERS MARKET, BY REGION, 2015-2022 (USD MILLION)
  • TABLE 48: NORTH AMERICA: BLADDER CANCER BIOMARKERS MARKET, BY COUNTRY, 2015-2022 (USD MILLION)
  • TABLE 49: EUROPE: BLADDER CANCER BIOMARKERS MARKET, BY COUNTRY, 2015-2022 (USD MILLION)
  • TABLE 50: ASIA PACIFIC: BLADDER CANCER BIOMARKERS MARKET, BY COUNTRY, 2015-2022 (USD MILLION)
  • TABLE 51: GLOBAL KIDNEY CANCER BIOMARKERS MARKET, BY REGION, 2015-2022 (USD MILLION)
  • TABLE 52: NORTH AMERICA: KIDNEY CANCER BIOMARKERS MARKET, BY COUNTRY, 2015-2022 (USD MILLION)
  • TABLE 53: EUROPE: KIDNEY CANCER BIOMARKERS MARKET, BY COUNTRY, 2015-2022 (USD MILLION)
  • TABLE 54: ASIA PACIFIC: KIDNEY CANCER BIOMARKERS MARKET, BY COUNTRY, 2015-2022 (USD MILLION)
  • TABLE 55: GLOBAL OTHER CANCER BIOMARKERS MARKET, BY REGION, 2015-2022 (USD MILLION)
  • TABLE 56: NORTH AMERICA: OTHER CANCER BIOMARKERS MARKET, BY COUNTRY, 2015-2022 (USD MILLION)
  • TABLE 57: EUROPE: OTHER CANCER BIOMARKERS MARKET, BY COUNTRY, 2015-2022 (USD MILLION)
  • TABLE 58: ASIA PACIFIC: OTHER CANCER BIOMARKERS MARKET, BY COUNTRY, 2015-2022 (USD MILLION)
  • TABLE 59: CANCER BIOMARKERS MARKET, BY PROFILING TECHNOLOGY, 2015-2022 (USD MILLION)
  • TABLE 60: CANCER BIOMARKERS MARKET FOR OMICS TECHNOLOGIES, BY TYPE, 2015-2022 (USD MILLION)
  • TABLE 61: CANCER BIOMARKERS MARKET FOR OMICS TECHNOLOGIES, BY REGION, 2015-2022 (USD MILLION)
  • TABLE 62: NORTH AMERICA: CANCER BIOMARKERS MARKET FOR OMICS TECHNOLOGIES, BY COUNTRY, 2015-2022 (USD MILLION)
  • TABLE 63: EUROPE: CANCER BIOMARKERS MARKET FOR OMICS TECHNOLOGIES, BY COUNTRY, 2015-2022 (USD MILLION)
  • TABLE 64: ASIA PACIFIC: CANCER BIOMARKERS MARKET FOR OMICS TECHNOLOGIES, BY COUNTRY, 2015-2022 (USD MILLION)
  • TABLE 65: CANCER BIOMARKERS MARKET FOR PROTEOMICS, BY REGION, 2015-2022 (USD MILLION)
  • TABLE 66: NORTH AMERICA: CANCER BIOMARKERS MARKET FOR PROTEOMICS, BY COUNTRY, 2015-2022 (USD MILLION)
  • TABLE 67: EUROPE: CANCER BIOMARKERS MARKET FOR PROTEOMICS, BY COUNTRY, 2015-2022 (USD MILLION)
  • TABLE 68: ASIA PACIFIC: CANCER BIOMARKERS MARKET FOR PROTEOMICS, BY COUNTRY, 2015-2022 (USD MILLION)
  • TABLE 69: CANCER BIOMARKERS MARKET FOR GENOMICS, BY TYPE, 2015-2022 (USD MILLION)
  • TABLE 70: CANCER BIOMARKERS MARKET FOR GENOMICS, BY REGION, 2015-2022 (USD MILLION)
  • TABLE 71: NORTH AMERICA: CANCER BIOMARKERS MARKET FOR GENOMICS, BY COUNTRY, 2015-2022 (USD MILLION)
  • TABLE 72: EUROPE: CANCER BIOMARKERS MARKET FOR GENOMICS, BY COUNTRY, 2015-2022 (USD MILLION)
  • TABLE 73: ASIA PACIFIC: CANCER BIOMARKERS MARKET FOR GENOMICS, BY COUNTRY, 2015-2022 (USD MILLION)
  • TABLE 74: CANCER BIOMARKERS MARKET FOR NGS, BY REGION, 2015-2022 (USD MILLION)
  • TABLE 75: NORTH AMERICA: CANCER BIOMARKERS MARKET FOR NGS, BY COUNTRY, 2015-2022 (USD MILLION)
  • TABLE 76: EUROPE: CANCER BIOMARKERS MARKET FOR NGS, BY COUNTRY, 2015-2022 (USD MILLION)
  • TABLE 77: ASIA PACIFIC: CANCER BIOMARKERS MARKET FOR NGS, BY COUNTRY, 2015-2022 (USD MILLION)
  • TABLE 78: CANCER BIOMARKERS MARKET FOR PCR, BY REGION, 2015-2022 (USD MILLION)
  • TABLE 79: NORTH AMERICA: CANCER BIOMARKERS MARKET FOR PCR, BY COUNTRY, 2015-2022 (USD MILLION)
  • TABLE 80: EUROPE: CANCER BIOMARKERS MARKET FOR PCR, BY COUNTRY, 2015-2022 (USD MILLION)
  • TABLE 81: ASIA PACIFIC: CANCER BIOMARKERS MARKET FOR PCR, BY COUNTRY, 2015-2022 (USD MILLION)
  • TABLE 82: CANCER BIOMARKERS MARKET FOR OTHER OMICS TECHNOLOGIES, BY REGION, 2015-2022 (USD MILLION)
  • TABLE 83: NORTH AMERICA: CANCER BIOMARKERS MARKET FOR OTHER OMICS TECHNOLOGIES, BY COUNTRY, 2015-2022 (USD MILLION)
  • TABLE 84: EUROPE: CANCER BIOMARKERS MARKET FOR OTHER OMICS TECHNOLOGIES, BY COUNTRY, 2015-2022 (USD MILLION)
  • TABLE 85: ASIA PACIFIC: CANCER BIOMARKERS MARKET FOR OTHER OMICS TECHNOLOGIES, BY COUNTRY, 2015-2022 (USD MILLION)
  • TABLE 86: CANCER BIOMARKERS MARKET FOR IMAGING TECHNOLOGIES, BY TYPE, 2015-2022 (USD MILLION)
  • TABLE 87: CANCER BIOMARKERS MARKET FOR IMAGING TECHNOLOGIES, BY REGION, 2015-2022 (USD MILLION)
  • TABLE 88: NORTH AMERICA: CANCER BIOMARKERS MARKET FOR IMAGING TECHNOLOGIES, BY COUNTRY, 2015-2022 (USD MILLION)
  • TABLE 89: EUROPE: CANCER BIOMARKERS MARKET FOR IMAGING TECHNOLOGIES, BY COUNTRY/REGION, 2015-2022 (USD MILLION)
  • TABLE 90: ASIA PACIFIC: CANCER BIOMARKERS MARKET FOR IMAGING TECHNOLOGIES, BY COUNTRY, 2015-2022 (USD MILLION)
  • TABLE 91: CANCER BIOMARKERS MARKET FOR ULTRASOUND, BY REGION, 2015-2022 (USD MILLION)
  • TABLE 92: NORTH AMERICA: CANCER BIOMARKERS MARKET FOR ULTRASOUND, BY COUNTRY, 2015-2022 (USD MILLION)
  • TABLE 93: EUROPE: CANCER BIOMARKERS MARKET FOR ULTRASOUND, BY COUNTRY, 2015-2022 (USD MILLION)
  • TABLE 94: ASIA PACIFIC: CANCER BIOMARKERS MARKET FOR ULTRASOUND, BY COUNTRY, 2015-2022 (USD MILLION)
  • TABLE 95: CANCER BIOMARKERS MARKET FOR CT, BY REGION, 2015-2022 (USD MILLION)
  • TABLE 96: NORTH AMERICA: CANCER BIOMARKERS MARKET FOR CT, BY COUNTRY, 2015-2022 (USD MILLION)
  • TABLE 97: EUROPE: CANCER BIOMARKERS MARKET FOR CT, BY COUNTRY, 2015-2022 (USD MILLION)
  • TABLE 98: ASIA PACIFIC: CANCER BIOMARKERS MARKET FOR CT, BY COUNTRY, 2015-2022 (USD MILLION)
  • TABLE 99: CANCER BIOMARKERS MARKET FOR MRI, BY REGION, 2015-2022 (USD MILLION)
  • TABLE 100: NORTH AMERICA: CANCER BIOMARKERS MARKET FOR MRI, BY COUNTRY, 2015-2022 (USD MILLION)
  • TABLE 101: EUROPE: CANCER BIOMARKERS MARKET FOR MRI, BY COUNTRY, 2015-2022 (USD MILLION)
  • TABLE 102: ASIA PACIFIC: CANCER BIOMARKERS MARKET FOR MRI, BY COUNTRY, 2015-2022 (USD MILLION)
  • TABLE 103: CANCER BIOMARKERS MARKET FOR PET, BY REGION, 2015-2022 (USD MILLION)
  • TABLE 104: NORTH AMERICA: CANCER BIOMARKERS MARKET FOR PET, BY COUNTRY, 2015-2022 (USD MILLION)
  • TABLE 105: EUROPE: CANCER BIOMARKERS MARKET FOR PET, BY COUNTRY, 2015-2022 (USD MILLION)
  • TABLE 106: ASIA PACIFIC: CANCER BIOMARKERS MARKET FOR PET, BY COUNTRY, 2015-2022 (USD MILLION)
  • TABLE 107: CANCER BIOMARKERS MARKET FOR MAMMOGRAPHY, BY REGION, 2015-2022 (USD MILLION)
  • TABLE 108: NORTH AMERICA: CANCER BIOMARKERS MARKET FOR MAMMOGRAPHY, BY COUNTRY, 2015-2022 (USD MILLION)
  • TABLE 109: EUROPE: CANCER BIOMARKERS MARKET FOR MAMMOGRAPHY, BY COUNTRY, 2015-2022 (USD MILLION)
  • TABLE 110: ASIA PACIFIC: CANCER BIOMARKERS MARKET FOR MAMMOGRAPHY, BY COUNTRY, 2015-2022 (USD MILLION)
  • TABLE 111: CANCER BIOMARKERS MARKET FOR IMMUNOASSAYS, BY REGION, 2015-2022 (USD MILLION)
  • TABLE 112: NORTH AMERICA: CANCER BIOMARKERS MARKET FOR IMMUNOASSAYS, BY COUNTRY, 2015-2022 (USD MILLION)
  • TABLE 113: EUROPE: CANCER BIOMARKERS MARKET FOR IMMUNOASSAYS, BY COUNTRY, 2015-2022 (USD MILLION)
  • TABLE 114: ASIA PACIFIC: CANCER BIOMARKERS MARKET FOR IMMUNOASSAYS, BY COUNTRY, 2015-2022 (USD MILLION)
  • TABLE 115: CANCER BIOMARKERS MARKET FOR CYTOGENETICS, BY REGION, 2015-2022 (USD MILLION)
  • TABLE 116: NORTH AMERICA: CANCER BIOMARKERS MARKET FOR CYTOGENETICS, BY COUNTRY, 2015-2022 (USD MILLION)
  • TABLE 117: EUROPE: CANCER BIOMARKERS MARKET FOR CYTOGENETICS, BY COUNTRY, 2015-2022 (USD MILLION)
  • TABLE 118: ASIA PACIFIC: CANCER BIOMARKERS MARKET FOR CYTOGENETICS, BY COUNTRY, 2015-2022 (USD MILLION)
  • TABLE 119: CANCER BIOMARKERS MARKET FOR ISH, BY REGION, 2015-2022 (USD MILLION)
  • TABLE 120: NORTH AMERICA: CANCER BIOMARKERS MARKET FOR ISH, BY COUNTRY, 2015-2022 (USD MILLION)
  • TABLE 121: EUROPE: CANCER BIOMARKERS MARKET FOR ISH, BY COUNTRY, 2015-2022 (USD MILLION)
  • TABLE 122: ASIA PACIFIC: CANCER BIOMARKERS MARKET FOR ISH, BY COUNTRY, 2015-2022 (USD MILLION)
  • TABLE 123: CANCER BIOMARKERS MARKET FOR OTHER CYTOGENETICS-BASED TESTS, BY REGION, 2015-2022 (USD MILLION)
  • TABLE 124: NORTH AMERICA: CANCER BIOMARKERS MARKET FOR OTHER CYTOGENETICS-BASED TESTS, BY COUNTRY, 2015-2022 (USD MILLION)
  • TABLE 125: EUROPE: CANCER BIOMARKERS MARKET FOR OTHER CYTOGENETICS-BASED TESTS, BY COUNTRY, 2015-2022 (USD MILLION)
  • TABLE 126: ASIA PACIFIC: CANCER BIOMARKERS MARKET FOR OTHER CYTOGENETICS-BASED TESTS, BY COUNTRY, 2015-2022 (USD MILLION)
  • TABLE 127: GLOBAL CANCER BIOMARKERS MARKET FOR BIOINFORMATICS, BY REGION, 2015-2022 (USD MILLION)
  • TABLE 128: NORTH AMERICA: CANCER BIOMARKERS MARKET FOR BIOINFORMATICS, BY COUNTRY, 2015-2022 (USD MILLION)
  • TABLE 129: EUROPE: CANCER BIOMARKERS MARKET FOR BIOINFORMATICS, BY COUNTRY, 2015-2022 (USD MILLION)
  • TABLE 130: ASIA PACIFIC: CANCER BIOMARKERS MARKET FOR BIOINFORMATICS, BY COUNTRY, 2015-2022 (USD MILLION)
  • TABLE 131: GLOBAL CANCER BIOMARKERS MARKET, BY APPLICATION, 2015-2022 (USD MILLION)
  • TABLE 132: GLOBAL CANCER BIOMARKERS MARKET FOR DIAGNOSTICS, BY REGION, 2015-2022 (USD MILLION)
  • TABLE 133: NORTH AMERICA: CANCER BIOMARKERS MARKET FOR DIAGNOSTICS, BY COUNTRY, 2015-2022 (USD MILLION)
  • TABLE 134: EUROPE: CANCER BIOMARKERS MARKET FOR DIAGNOSTICS, BY COUNTRY, 2015-2022 (USD MILLION)
  • TABLE 135: ASIA PACIFIC: CANCER BIOMARKERS MARKET FOR DIAGNOSTICS, BY COUNTRY, 2015-2022 (USD MILLION)
  • TABLE 136: GLOBAL CANCER BIOMARKERS MARKET FOR RESEARCH AND DEVELOPMENT, BY REGION, 2015-2022 (USD MILLION)
  • TABLE 137: NORTH AMERICA: CANCER BIOMARKERS MARKET FOR RESEARCH AND DEVELOPMENT, BY COUNTRY, 2015-2022 (USD MILLION)
  • TABLE 138: EUROPE: CANCER BIOMARKERS MARKET FOR RESEARCH AND DEVELOPMENT, BY COUNTRY, 2015-2022 (USD MILLION)
  • TABLE 139: ASIA PACIFIC: CANCER BIOMARKERS MARKET FOR RESEARCH AND DEVELOPMENT, BY COUNTRY, 2015-2022 (USD MILLION)
  • TABLE 140: GLOBAL CANCER BIOMARKERS MARKET FOR PROGNOSTICS, BY REGION, 2015-2022 (USD MILLION)
  • TABLE 141: NORTH AMERICA: CANCER BIOMARKERS MARKET FOR PROGNOSTICS, BY COUNTRY, 2015-2022 (USD MILLION)
  • TABLE 142: EUROPE: CANCER BIOMARKERS MARKET FOR PROGNOSTICS, BY COUNTRY, 2015-2022 (USD MILLION)
  • TABLE 143: ASIA PACIFIC: CANCER BIOMARKERS MARKET FOR PROGNOSTICS, BY COUNTRY, 2015-2022 (USD MILLION)
  • TABLE 144: GLOBAL CANCER BIOMARKERS MARKET FOR RISK ASSESSMENT, BY REGION, 2015-2022 (USD MILLION)
  • TABLE 145: NORTH AMERICA: CANCER BIOMARKERS MARKET FOR RISK ASSESSMENT, BY COUNTRY, 2015-2022 (USD MILLION)
  • TABLE 146: EUROPE: CANCER BIOMARKERS MARKET FOR RISK ASSESSMENT, BY COUNTRY, 2015-2022 (USD MILLION)
  • TABLE 147: ASIA PACIFIC: CANCER BIOMARKERS MARKET FOR RISK ASSESSMENT, BY COUNTRY, 2015-2022 (USD MILLION)
  • TABLE 148: GLOBAL CANCER BIOMARKERS MARKET FOR OTHER APPLICATIONS, BY REGION, 2015-2022 (USD MILLION)
  • TABLE 149: NORTH AMERICA: CANCER BIOMARKERS MARKET FOR OTHER APPLICATIONS, BY COUNTRY, 2015-2022 (USD MILLION)
  • TABLE 150: EUROPE: CANCER BIOMARKERS MARKET FOR OTHER APPLICATIONS, BY COUNTRY, 2015-2022 (USD MILLION)
  • TABLE 151: ASIA PACIFIC: CANCER BIOMARKERS MARKET FOR OTHER APPLICATIONS, BY COUNTRY, 2015-2022 (USD MILLION)
  • TABLE 152: GLOBAL CANCER BIOMARKERS MARKET, BY REGION, 2015-2022 (USD MILLION)
  • TABLE 153: NORTH AMERICA: CANCER BIOMARKERS MARKET, BY COUNTRY, 2015-2022 (USD MILLION)
  • TABLE 154: NORTH AMERICA: CANCER BIOMARKERS MARKET, BY CANCER TYPE, 2015-2022 (USD MILLION)
  • TABLE 155: NORTH AMERICA: CANCER BIOMARKERS MARKET, BY BIOMARKER TYPE, 2015-2022 (USD MILLION)
  • TABLE 156: NORTH AMERICA: CANCER BIOMARKERS MARKET, BY PROFILING TECHNOLOGY, 2015-2022 (USD MILLION)
  • TABLE 157: NORTH AMERICA: OMICS TECHNOLOGIES MARKET, BY TYPE, 2015-2022 (USD MILLION)
  • TABLE 158: NORTH AMERICA: GENOMICS TECHNOLOGIES MARKET, BY TYPE, 2015-2022 (USD MILLION)
  • TABLE 159: NORTH AMERICA: IMAGING TECHNOLOGIES MARKET, BY TYPE, 2015-2022 (USD MILLION)
  • TABLE 160: NORTH AMERICA: CYTOGENETICS MARKET, BY TYPE, 2015-2022 (USD MILLION)
  • TABLE 161: NORTH AMERICA: CANCER BIOMARKERS MARKET, BY APPLICATION, 2015-2022 (USD MILLION)
  • TABLE 162: US: CANCER BIOMARKERS MARKET, BY CANCER TYPE, 2015-2022 (USD MILLION)
  • TABLE 163: US: CANCER BIOMARKERS MARKET, BY BIOMARKER TYPE, 2015-2022 (USD MILLION)
  • TABLE 164: US: CANCER BIOMARKERS MARKET, BY PROFILING TECHNOLOGY, 2015-2022 (USD MILLION)
  • TABLE 165: US: OMICS TECHNOLOGIES MARKET, BY TYPE, 2015-2022 (USD MILLION)
  • TABLE 166: US: GENOMICS TECHNOLOGIES MARKET, BY TYPE, 2015-2022 (USD MILLION)
  • TABLE 167: US: IMAGING TECHNOLOGIES MARKET, BY TYPE, 2015-2022 (USD MILLION)
  • TABLE 168: US: CYTOGENETICS MARKET, BY TYPE, 2015-2022 (USD MILLION)
  • TABLE 169: US: CANCER BIOMARKERS MARKET, BY APPLICATION, 2015-2022 (USD MILLION)
  • TABLE 170: CANADA: CANCER BIOMARKERS MARKET, BY CANCER TYPE, 2015-2022 (USD MILLION)
  • TABLE 171: CANADA: CANCER BIOMARKERS MARKET, BY BIOMARKER TYPE, 2015-2022 (USD MILLION)
  • TABLE 172: CANADA: CANCER BIOMARKERS MARKET, BY PROFILING TECHNOLOGY, 2015-2022 (USD MILLION)
  • TABLE 173: CANADA: OMICS TECHNOLOGIES MARKET, BY TYPE, 2015-2022 (USD MILLION)
  • TABLE 174: CANADA: GENOMICS TECHNOLOGIES MARKET, BY TYPE, 2015-2022 (USD MILLION)
  • TABLE 175: CANADA: IMAGING TECHNOLOGIES MARKET, BY TYPE, 2015-2022 (USD MILLION)
  • TABLE 176: CANADA: CYTOGENETICS MARKET, BY TYPE, 2015-2022 (USD MILLION)
  • TABLE 177: CANADA: CANCER BIOMARKERS MARKET, BY APPLICATION, 2015-2022 (USD MILLION)
  • TABLE 178: EUROPE :CANCER BIOMARKERS MARKET, BY COUNTRY, 2015-2022 (USD MILLION)
  • TABLE 179: EUROPE: CANCER BIOMARKERS MARKET, BY CANCER TYPE, 2015-2022 (USD MILLION)
  • TABLE 180: EUROPE: CANCER BIOMARKERS MARKET, BY BIOMARKER TYPE, 2015-2022 (USD MILLION)
  • TABLE 181: EUROPE: CANCER BIOMARKERS MARKET, BY PROFILING TECHNOLOGY, 2015-2022 (USD MILLION)
  • TABLE 182: EUROPE: OMICS TECHNOLOGIES MARKET, BY TYPE, 2015-2022 (USD MILLION)
  • TABLE 183: EUROPE: GENOMICS TECHNOLOGIES MARKET, BY TYPE, 2015-2022 (USD MILLION)
  • TABLE 184: EUROPE: IMAGING TECHNOLOGIES MARKET, BY TYPE, 2015-2022 (USD MILLION)
  • TABLE 185: EUROPE: CYTOGENETICS MARKET, BY TYPE, 2015-2022 (USD MILLION)
  • TABLE 186: EUROPE: CANCER BIOMARKERS MARKET, BY APPLICATION, 2015-2022 (USD MILLION)
  • TABLE 187: GERMANY: CANCER BIOMARKERS MARKET, BY CANCER TYPE, 2015-2022 (USD MILLION)
  • TABLE 188: GERMANY: CANCER BIOMARKERS MARKET, BY BIOMARKER TYPE, 2015-2022 (USD MILLION)
  • TABLE 189: GERMANY: CANCER BIOMARKERS MARKET, BY PROFILING TECHNOLOGY, 2015-2022 (USD MILLION)
  • TABLE 190: GERMANY: OMICS TECHNOLOGIES MARKET, BY TYPE, 2015-2022 (USD MILLION)
  • TABLE 191: GERMANY: GENOMICS TECHNOLOGIES MARKET, BY TYPE, 2015-2022 (USD MILLION)
  • TABLE 192: GERMANY: IMAGING TECHNOLOGIES MARKET, BY TYPE, 2015-2022 (USD MILLION)
  • TABLE 193: GERMANY: CYTOGENETICS MARKET, BY TYPE, 2015-2022 (USD MILLION)
  • TABLE 194: GERMANY: CANCER BIOMARKERS MARKET, BY APPLICATION, 2015-2022 (USD MILLION)
  • TABLE 195: UK: CANCER BIOMARKERS MARKET, BY CANCER TYPE, 2015-2022 (USD MILLION)
  • TABLE 196: UK: CANCER BIOMARKERS MARKET, BY BIOMARKER TYPE, 2015-2022 (USD MILLION)
  • TABLE 197: UK: CANCER BIOMARKERS MARKET, BY PROFILING TECHNOLOGY, 2015-2022 (USD MILLION)
  • TABLE 198: UK: OMICS TECHNOLOGIES MARKET, BY TYPE, 2015-2022 (USD MILLION)
  • TABLE 199: UK: GENOMICS TECHNOLOGIES MARKET, BY TYPE, 2015-2022 (USD MILLION)
  • TABLE 200: UK: IMAGING TECHNOLOGIES MARKET, BY TYPE, 2015-2022 (USD MILLION)
  • TABLE 201: UK: CYTOGENETICS MARKET, BY TYPE, 2015-2022 (USD MILLION)
  • TABLE 202: UK: CANCER BIOMARKERS MARKET, BY APPLICATION , 2015-2022 (USD MILLION)
  • TABLE 203: FRANCE: CANCER BIOMARKERS MARKET, BY CANCER TYPE, 2015-2022 (USD MILLION)
  • TABLE 204: FRANCE: CANCER BIOMARKERS MARKET, BY BIOMARKER TYPE, 2015-2022 (USD MILLION)
  • TABLE 205: FRANCE: CANCER BIOMARKERS MARKET, BY PROFILING TECHNOLOGY, 2015-2022 (USD MILLION)
  • TABLE 206: FRANCE: OMICS TECHNOLOGIES MARKET, BY TYPE, 2015-2022 (USD MILLION)
  • TABLE 207: FRANCE: GENOMICS TECHNOLOGIES MARKET, BY TYPE, 2015-2022 (USD MILLION)
  • TABLE 208: FRANCE: IMAGING TECHNOLOGIES MARKET, BY TYPE, 2015-2022 (USD MILLION)
  • TABLE 209: FRANCE: CYTOGENETICS MARKET, BY TYPE, 2015-2022 (USD MILLION)
  • TABLE 210: FRANCE: CANCER BIOMARKERS MARKET, BY APPLICATION, 2015-2022 (USD MILLION)
  • TABLE 211: ITALY: CANCER BIOMARKERS MARKET, BY CANCER TYPE, 2015-2022 (USD MILLION)
  • TABLE 212: ITALY: CANCER BIOMARKERS MARKET, BY BIOMARKER TYPE, 2015-2022 (USD MILLION)
  • TABLE 213: ITALY: CANCER BIOMARKERS MARKET, BY PROFILING TECHNOLOGY, 2015-2022 (USD MILLION)
  • TABLE 214: ITALY: OMICS TECHNOLOGIES MARKET, BY TYPE, 2015-2022 (USD MILLION)
  • TABLE 215: ITALY: GENOMICS TECHNOLOGIES MARKET, BY TYPE, 2015-2022 (USD MILLION)
  • TABLE 216: ITALY: IMAGING TECHNOLOGIES MARKET, BY TYPE, 2015-2022 (USD MILLION)
  • TABLE 217: ITALY: CYTOGENETICS MARKET, BY TYPE, 2015-2022 (USD MILLION)
  • TABLE 218: ITALY: CANCER BIOMARKERS MARKET, BY APPLICATION, 2015-2022 (USD MILLION)
  • TABLE 219: SPAIN: CANCER BIOMARKERS MARKET, BY CANCER TYPE, 2015-2022 (USD MILLION)
  • TABLE 220: SPAIN: CANCER BIOMARKERS MARKET, BY BIOMARKER TYPE, 2015-2022 (USD MILLION)
  • TABLE 221: SPAIN: CANCER BIOMARKERS MARKET, BY PROFILING TECHNOLOGY, 2015-2022 (USD MILLION)
  • TABLE 222: SPAIN: OMICS TECHNOLOGIES MARKET, BY TYPE, 2015-2022 (USD MILLION)
  • TABLE 223: SPAIN: GENOMICS TECHNOLOGIES MARKET, BY TYPE, 2015-2022 (USD MILLION)
  • TABLE 224: SPAIN: IMAGING TECHNOLOGIES MARKET, BY TYPE, 2015-2022 (USD MILLION)
  • TABLE 225: SPAIN: CYTOGENETICS MARKET, BY TYPE, 2015-2022 (USD MILLION)
  • TABLE 226: SPAIN: CANCER BIOMARKERS MARKET, BY APPLICATION, 2015-2022 (USD MILLION)
  • TABLE 227: ROE: CANCER BIOMARKERS MARKET, BY CANCER TYPE, 2015-2022 (USD MILLION)
  • TABLE 228: ROE: CANCER BIOMARKERS MARKET, BY TYPE, 2015-2022 (USD MILLION)
  • TABLE 229: ROE: CANCER BIOMARKERS MARKET, BY PROFILING TECHNOLOGY, 2015-2022 (USD MILLION)
  • TABLE 230: ROE: OMICS TECHNOLOGIES MARKET, BY TYPE, 2015-2022 (USD MILLION)
  • TABLE 231: ROE: GENOMICS TECHNOLOGIES MARKET, BY TYPE, 2015-2022 (USD MILLION)
  • TABLE 232: ROE: IMAGING TECHNOLOGIES MARKET, 2015-2022 (USD MILLION)
  • TABLE 233: ROE: CYTOGENETICS MARKET, BY TYPE, 2015-2022 (USD MILLION)
  • TABLE 234: ROE: CANCER BIOMARKERS MARKET, BY APPLICATION, 2015-2022 (USD MILLION)
  • TABLE 235: ASIA PACIFIC: CANCER BIOMARKERS MARKET, BY COUNTRY, 2015-2022 (USD MILLION)
  • TABLE 236: ASIA PACIFIC: CANCER BIOMARKERS MARKET, BY CANCER TYPE, 2015-2022 (USD MILLION)
  • TABLE 237: ASIA PACIFIC: CANCER BIOMARKERS MARKET, BY TYPE, 2015-2022 (USD MILLION)
  • TABLE 238: ASIA PACIFIC: CANCER BIOMARKERS MARKET, BY PROFILING TECHNOLOGY, 2015-2022 (USD MILLION)
  • TABLE 239: ASIA PACIFIC: OMICS TECHNOLOGIES MARKET, BY TYPE, 2015-2022 (USD MILLION)
  • TABLE 240: ASIA PACIFIC: GENOMICS TECHNOLOGIES MARKET, BY TYPE, 2015-2022 (USD MILLION)
  • TABLE 241: ASIA PACIFIC: IMAGING TECHNOLOGIES MARKET, BY TYPE, 2015-2022 (USD MILLION)
  • TABLE 242: ASIA PACIFIC: CYTOGENETICS MARKET, BY TYPE, 2015-2022 (USD MILLION)
  • TABLE 243: ASIA PACIFIC: CANCER BIOMARKERS MARKET, BY APPLICATION, 2015-2022 (USD MILLION)
  • TABLE 244: JAPAN: CANCER BIOMARKERS MARKET, BY CANCER TYPE, 2015-2022 (USD MILLION)
  • TABLE 245: JAPAN: CANCER BIOMARKERS MARKET, BY TYPE, 2015-2022 (USD MILLION)
  • TABLE 246: JAPAN: CANCER BIOMARKERS MARKET, BY PROFILING TECHNOLOGY, 2015-2022 (USD MILLION)
  • TABLE 247: JAPAN: OMICS TECHNOLOGIES MARKET, BY TYPE, 2015-2022 (USD MILLION)
  • TABLE 248: JAPAN: GENOMICS TECHNOLOGIES MARKET, BY TYPE, 2015-2022 (USD MILLION)
  • TABLE 249: JAPAN: IMAGING TECHNOLOGIES MARKET, BY TYPE, 2015-2022 (USD MILLION)
  • TABLE 250: JAPAN: CYTOGENETICS MARKET, BY TYPE, 2015-2022 (USD MILLION)
  • TABLE 251: JAPAN: CANCER BIOMARKERS MARKET, BY APPLICATION, 2015-2022 (USD MILLION)
  • TABLE 252: REST OF APAC: CANCER BIOMARKERS MARKET, BY CANCER TYPE, 2015-2022 (USD MILLION)
  • TABLE 253: REST OF APAC: CANCER BIOMARKERS MARKET, BY BIOMARKER TYPE, 2015-2020 (USD MILLION)
  • TABLE 254: REST OF APAC: CANCER BIOMARKERS MARKET, BY PROFILING TECHNOLOGY, 2015-2022 (USD MILLION)
  • TABLE 255: REST OF APAC: OMICS TECHNOLOGIES MARKET, BY TYPE, 2015-2022 (USD MILLION)
  • TABLE 256: REST OF APAC: GENOMICS TECHNOLOGIES MARKET, BY TYPE, 2015-2022 (USD MILLION)
  • TABLE 257: REST OF APAC: IMAGING TECHNOLOGIES MARKET, BY TYPE, 2015-2022 (USD MILLION)
  • TABLE 258: REST OF APAC: CYTOGENETICS MARKET, BY TYPE, 2015-2022 (USD MILLION)
  • TABLE 259: REST OF APAC: CANCER BIOMARKERS MARKET, BY APPLICATION, 2015-2022 (USD MILLION)
  • TABLE 260: ROW: CANCER BIOMARKERS MARKET, BY CANCER TYPE, 2015-2022 (USD MILLION)
  • TABLE 261: ROW: CANCER BIOMARKERS MARKET, BY TYPE, 2015-2022 (USD MILLION)
  • TABLE 262: ROW: CANCER BIOMARKERS MARKET, BY PROFILING TECHNOLOGY, 2015-2022 (USD MILLION)
  • TABLE 263: ROW: OMICS TECHNOLOGIES MARKET, BY TYPE, 2015-2022 (USD MILLION)
  • TABLE 264: ROW: GENOMICS TECHNOLOGIES MARKET, BY TYPE, 2015-2022 (USD MILLION)
  • TABLE 265: ROW: IMAGING TECHNOLOGIES MARKET, BY TYPE, 2015-2022 (USD MILLION)
  • TABLE 266: ROW: CYTOGENETICS MARKET, BY TYPE, 2015-2022 (USD MILLION)
  • TABLE 267: ROW: CANCER BIOMARKERS MARKET, BY APPLICATION, 2015-2022 (USD MILLION)
  • TABLE 268: RANK OF COMPANIES IN THE GLOBAL CANCER BIOMARKERS MARKET, 2016

LIST OF FIGURES

  • FIGURE 1: RESEARCH DESIGN
  • FIGURE 2: BOTTOM-UP APPROACH
  • FIGURE 3: TOP-DOWN APPROACH
  • FIGURE 4: BREAKDOWN OF PRIMARY INTERVIEWS: BY COMPANY TYPE, DESIGNATION, AND REGION
  • FIGURE 5: DATA TRIANGULATION
  • FIGURE 6: CANCER BIOMARKER MARKET, BY CANCER TYPE, 2017 VS. 2022 (USD MILLION)
  • FIGURE 7: CANCER BIOMARKER MARKET, BY BIOMARKER TYPE, 2017 VS. 2022 (USD MILLION)
  • FIGURE 8: CANCER BIOMARKER MARKET, BY APPLICATION, 2017 VS. 2022 (USD MILLION)
  • FIGURE 9: CANCER BIOMARKER MARKET, BY PROFILING TECHNOLOGY, 2017 VS. 2022 (USD MILLION)
  • FIGURE 10: GEOGRAPHICAL SNAPSHOT OF THE CANCER BIOMARKER MARKET
  • FIGURE 11: TECHNOLOGICAL ADVANCEMENT IS A MAJOR DRIVER FOR THE CANCER BIOMARKERS MARKET GROWTH IN 2017
  • FIGURE 12: CANCER BIOMARKERS MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES
  • FIGURE 13: GENETIC BIOMARKERS TO REGISTER THE HIGHEST CAGR IN THE FORECAST PERIOD
  • FIGURE 14: MUTATION RATE OF CELL SURFACE RECEPTOR BIOMARKERS IN BREAST TUMOR
  • FIGURE 15: GLOBAL CANCER BIOMARKERS MARKET, BY CANCER TYPE
  • FIGURE 16: OMICS TECHNOLOGIES WILL CONTINUE TO DOMINATE THE GLOBAL CANCER BIOMARKERS MARKET IN 2022
  • FIGURE 17: DIAGNOSTICS APPLICATION SEGMENT TO DOMINATE THE CANCER BIOMARKERS MARKET IN 2017
  • FIGURE 18: CANCER BIOMARKERS MARKET: GEOGRAPHIC SNAPSHOT (2017-2022)
  • FIGURE 19: NORTH AMERICA MARKET SNAPSHOT
  • FIGURE 20: EUROPE MARKET SNAPSHOT
  • FIGURE 21: ASIA PACIFIC MARKET SNAPSHOT
  • FIGURE 22: THERMO FISHER SCIENTIFIC: COMPANY SNAPSHOT (2016)
  • FIGURE 23: BIO-RAD LABORATORIES: COMPANY SNAPSHOT (2016)
  • FIGURE 24: ROCHE DIAGNOSTICS: COMPANY SNAPSHOT (2016)
  • FIGURE 25: QIAGEN N.V.: COMPANY SNAPSHOT (2016)
  • FIGURE 26: ILLUMINA: COMPANY SNAPSHOT (2016)
  • FIGURE 27: GE HEALTHCARE: COMPANY SNAPSHOT (2016)
  • FIGURE 28: AGILENT TECHNOLOGIES: COMPANY SNAPSHOT (2016)
  • FIGURE 29: BIOMERIEUX SA: COMPANY SNAPSHOT (2016)
  • FIGURE 30: MERCK & CO.INC.: COMPANY SNAPSHOT (2016)
  • FIGURE 31: ABBOTT LABORATORIES: COMPANY SNAPSHOT (2016)
  • FIGURE 32: BECTON, DICKINSON AND COMPANY : COMPANY SNAPSHOT (2016)
  • FIGURE 33: DANAHER CORPORATION: COMPANY SNAPSHOT (2016)
  • FIGURE 34: MYRIAD GENETICS INC.: COMPANY SNAPSHOT (2016)
  • FIGURE 35: SYSMEX CORPORATION: COMPANY SNAPSHOT (2016)
  • FIGURE 36: HOLOGIC: COMPANY SNAPSHOT (2016)
  • FIGURE 37: QUEST DIAGNOSTICS: COMPANY SNAPSHOT (2016)
Back to Top